Previous Article | Next Article ![]()
Journal of Virology, July 2001, p. 6310-6320, Vol. 75, No. 14
Department of Pediatrics, Mount Sinai School
of Medicine, New York, New York 10029
Received 29 January 2001/Accepted 18 April 2001
Entry and fusion of human parainfluenza virus type 3 (HPF3)
requires interaction of the viral hemagglutinin-neuraminidase (HN)
glycoprotein with its sialic acid receptor.
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
(4-GU-DANA; zanamivir), a sialic acid transition-state analog designed
to fit the influenza virus neuraminidase catalytic site, possesses
antiviral activity at nanomolar concentrations in vitro. We have shown
previously that 4-GU-DANA also inhibits both HN-mediated binding of
HPF3 to host cell receptors and HN's neuraminidase activity. In the
present study, a 4-GU-DANA-resistant HPF3 virus variant (ZM1) was
generated by serial passage in the presence of 4-GU-DANA. ZM1 exhibited
a markedly fusogenic plaque morphology and harbored two HN gene
mutations resulting in two amino acid alterations, T193I and I567V.
Another HPF3 variant studied in parallel, C-0, shared an alteration at
T193 and exhibited similar plaque morphology but was not resistant to
4-GU-DANA. Neuraminidase assays revealed a 15-fold reduction in
4-GU-DANA sensitivity for ZM1 relative to the wild type (WT) and C-0.
The ability of ZM1 to bind sialic acid receptors was inhibited 10-fold
less than for both WT and C-0 in the presence of 1 mM 4-GU-DANA. ZM1
also retained infectivity at 15-fold-higher concentrations of 4-GU-DANA than WT and C-0. A single amino acid alteration at HN residue 567 confers these 4-GU-DANA-resistant properties. An understanding of ZM1
and other escape variants provides insight into the effects of this
small molecule on HN function as well as the role of the HN
glycoprotein in HPF3 pathogenesis.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.14.6310-6320.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
A Single Amino Acid Alteration in the Human
Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Glycoprotein
Confers Resistance to the Inhibitory Effects of Zanamivir on
Receptor Binding and Neuraminidase Activity
*
Corresponding author. Mailing address: Department of
Pediatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029. Phone: (212) 241-6930. Fax: (212) 426-4813. E-mail:
Anne.moscona{at}mssm.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»